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Background: Academic detailing (AD; also known as educational visiting) facilitates the translation of evidence into
practice and has been widely adopted internationally to facilitate practice change. The potential of AD linked to a
specific patient and delivered by a specialist physician to general practitioners has not been evaluated.
This pilot study assessed the feasibility and acceptability of AD on the knowledge and confidence of GPs caring for
people with advanced cancer who had breathlessness at the end of life.
Methods: In this randomised controlled pilot, 35 patient/GP dyads were randomised to AD or usual care. Key
messages included: ensuring reversible causes were optimally treated; non-pharmacological and pharmacological
treatments were considered; and oxygen considered for hypoxaemic patients.
Results: Acceptability: The majority of GPs randomised to AD agreed to participate, reporting benefits to practice. The
majority of GPs in the control group requested a copy of academic detailing written materials at study completion.
Feasibility: AD visits to GPs’ offices could be timetabled reasonably easily, with 24 detailing visits occurring.
Self-reported knowledge and beliefs: Ninety two percent of GPs reported the topics covered in the AD sessions were
useful, with 83 % reporting an increase in knowledge and confidence. AD sessions resulted in 58 % of GPs reporting a
change in their approach to the management of breathlessness. By contrast, 81 % of the usual care group reported
low confidence in the management and knowledge of breathlessness.
Conclusion: AD was acceptable and feasible to participating GPs. This pilot supports proceeding to a fully powered study.
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Breathlessness that persists despite maximal therapy of
treatable causes affects up to 70 % of people with advanced
life-limiting illnesses [1-4]. The sensation of breathlessness
creates significant distress for patients and their caregivers
[5]. Clinical management guidelines that deal with the
management of single aetiologies may be of little help to
clinicians when faced with patients who have several fac-
tors contributing to their breathlessness at the end-of-life
[6]. Further, national and international guidelines for the* Correspondence: david.currow@flinders.edu.au
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unless otherwise stated.symptomatic management of breathlessness that persists
despite optimal treatment of the underlying causes have
changed markedly in the last 15 years [7-10].
A recent Australian population study (Caretrack)
highlighted the challenges and evidence to practice gaps
existing in Australia [9]. Academic detailing (AD) uses an
evidence-based approach that establishes an understand-
ing of a practitioner’s beliefs and behaviours in relation to
the issue at hand and then proceeds to tailor up to three
key messages in response. There is evidence that AD im-
proves evidence-based prescribing of medicines and other
changes in practice are well established and underpinned
by robust health service intervention studies [11-13].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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mised pilot study aimed to determine the feasibility and
acceptability of using academic detailing to improve un-
derstanding of the current evidence about assessing and
treating chronic refractory breathlessness. The model of
academic detailing included two unique features that
may have widespread relevance to future AD research
and practice:
 Linking GP educational visits to a specific patient
with the index condition/symptom; and
 Using a specialist physician to provide the
detailing visits.
The study also sought any evidence of a change in GPs
knowledge or behaviour that could inform calculations
for a fully powered randomised controlled trial.
Methods
This pilot study was a randomised, controlled, non-
blinded, parallel group study comparing AD by a specialist
palliative care/respiratory physician for general practi-
tioners caring for a specific patient with breathlessness at
the time of referral to a specialist palliative care service
with usual care.
Setting and participants
The study took place in Adelaide, South Australia. GPs
were recruited after referral of one of their patients with
breathlessness to the regional palliative care service. En-
rolment required consent of both the patient and his/
her GP. The study identified patients with cancer re-
ferred to the palliative care service with moderate to se-
vere breathlessness at rest or on minimal exertion.
Other inclusion criteria included: able to understand
English; an Medical Research Council breathlessness
score of equal to or greater than three; considered by
their GP to have a life expectancy of more than 2 weeks;
and opioid naïve.
Feasibility and acceptability
Feasibility and acceptability were assessed by investigating
GP’s acceptability of the AD including the response rate
and level of participation in the discussions related to a
specific patient for whom they were providing care. GPs
self-reported changes in beliefs, behaviours or confidence
about the diagnosis and treatment of refractory breath-
lessness were assessed using a 21-item questionnaire
(appendix 1).
Randomisation
Patient/GP dyad participants were allocated by block
randomisation (1:1) to receive one of the two studyarms. Randomisation was performed by a computer
random allocation program.
Analysis
Data were entered into the CareSearch data manage-
ment system. Recruitment of patient/ GP dyads, the re-
sponse rate and level of participation in AD by GPs, and
evidence of self-reported changes in the beliefs, behav-
iours or confidence of GPs about the diagnosis and
treatment of refractory breathlessness in the intervention
group are described.
Details of academic detailing
Uniquely, the detailer was a palliative medicine and re-
spiratory physician and had a pre-existing relationship
with many of the participating GPs, in his usual role of
providing specialist consultations. One author (DR), a
senior pharmacist and recognised expert in the field of
AD, provided training and support to the physician. Two
visits were made as part of the protocol at mutually con-
venient times to provide individualised guidance. AD
visits were planned at 2 and 4 weeks following the pa-
tient’s enrolment in the study to provide adequate time
for the patient to visit their GP and for possible imple-
mentation of the new knowledge to occur. Sessions cov-
ered the following four evidence-based themes that had
been developed from the literature: reversible causes had
been considered and optimally managed (level 4 evidence)
[15-17]; non-pharmacological measures including walking
aids, breathing training and pulmonary rehabilitation had
been considered (level 1 evidence) [18]; evidence-based
pharmacological interventions include regular, low-dose
opioids (level 1 evidence) [19-21]; and the consideration
of oxygen if therapeutically indicated (level 1 evidence)
[22]. The detailer discussed identification and diagnosis of
potentially reversible causes of breathlessness in the spe-
cific patient that had triggered participation in the study.
Additionally, GPs were provided with supporting written
information [6] prepared by the research team, including
a copy of the current edition of the Palliative Care Thera-
peutic Guidelines [13].
Outcome measures
The primary outcome measure was the uptake of key
messages by GPs. GPs in both arms of the study com-
pleted a 21-item questionnaire compiled by the research
team about their knowledge, experience and confidence
regarding the management of breathlessness for people
at the end of life. GPs in the intervention group com-
pleted the questionnaire following the two AD visits.
GPs in the control arm completed a modified version of
the questionnaire at 10 weeks post enrolment.
Ethics approval was granted from the Repatriation
General Hospital’s Human Research Ethics Committee.
Patients and their GPs provided written informed consent.
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Participants
GP Characteristics
GPs (n = 35) were recruited from a variety of practice set-
tings including individual and group practices. Clinicians
were experienced general practitioners with a median of
28 years since graduation.
Patient characteristics
Patients ranged in age between 47 and 88 years. The ma-
jority (n = 20) had a diagnosis of lung cancer. Other re-
corded sites of malignancy included colorectal (3) [23];
other GI tract (1); urological (1) [23]; haematological (1);
skin (1); breast (1); prostate (1); pancreas (3); other (3).
Participation and response rate
In total, 72 patients were screened. A total of 35 patient/
GP dyads were randomised to the study, 17 to AD visits.
The remaining patient/GP dyads (37) were excluded be-
cause: patients died prior to an AD visit occurring (5); the
GPs were already closely involved with the palliative care
service (5); patients were deemed by the research nurse
not to be able to consent due to cognitive impairment (6);
and patients had a poor life-expectancy (prognosis of less
than 2 weeks) (4); Six patients did not meet the study cri-
teria for breathlessness. Three patients declined to partici-
pate in the study stating “feeling too unwell” and oneFig. 1 Study flow chartpatient declined stating “too burdensome” as the reason.
Five GPs declined the offer to participate (stating time
constraints as the primary reason); No reason was re-
corded for two GP/patient dyads [Fig. 1].
Acceptability
Most GPs randomised to the AD intervention agreed to
participate in the AD visits. All GPs but one in the inter-
vention group who completed the questionnaire (n =10),
reported that they found the visits useful for their prac-
tice [Table 1].
The majority of GPs in the control group who com-
pleted the questionnaire (n = 15) requested a copy of the
supporting written materials.
Feasibility
As noted, five patients died before an AD visit could
occur. Most visits to GPs’ offices could be timetabled
reasonably easily although difficulty doing this was the
major reason for visits not occurring. Thirteen first visits
and 11 s visits occurred.
Academic detailing visits
In the intervention group, GPs found AD visits helpful.
All but one GP in the intervention group reported that
the AD materials covered the clinical area of breathless-
ness and were useful to their practice. All but two GPs
Table 1 Qualitative feedback from general practitioners
participating in academic detailing provided by a consultant
physician on the assessment and treatment of chronic refractory
breathlessness
GP (AD group) comments
I am very keen for my patients to be involved in trials as they learn
more about their condition, get the benefit of latest ideas, and as a
result I learn from this.
Quick, informative. I was unaware of the benefit of morphine for cancer
related breathlessness
It was probably excellent for some practices
Well-done
Very good to have one to one discussion. I already had book but didn’t
know about web resources
Limited usefulness
Informative, practical and helpful
Reinforcing the need to exclude reversible causes. Tricks on
commencing morphine for dyspnoea in patients already on opioids.
Reinforcing current knowledge
Clarified use of narcotics; refined use of nebulised medications
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knowledge and confidence in the management of breath-
lessness. The AD session resulted in 58 % of GPs in the
intervention group reporting a change in their approach
to the management of breathlessness.
Conversely, 81 % of the usual care group reported low
confidence in the management and knowledge of breath-
lessness before the detailing material was provided to
them at the end of the study.Time invested
The duration of visits ranged between 15 and 45 min.
Adding travel time to this brought the total time per
visit to between 60 and 90 min. Administrative time in
organising each visit required approximately 30 min.
Total direct costs in today’s terms that include general
practitioner, consultant physician and administrative
time brought each visit to between AU$290 and
AU$435.Discussion
This randomised, pilot study provided data to assess the
feasibility, acceptability and changes in knowledge and
behaviours in response to AD on the diagnosis and man-
agement of refractory breathlessness relating to specific
patients delivered by a local respiratory physician to
GPs. Given the burden of refractory breathlessness in
the community, these findings suggest that a fully pow-
ered study is justified given the rapidly evolving evidence
base in safely treating refractory breathlessness at the
end of life.Patients with multi-morbidities and considerable symp-
tom burden are the largest users of health services [24]
and require careful clinical management [25]. Despite this,
clinical guidelines most often provide guidance related to
single aetiology and deal poorly with multi-morbidity,
therefore not reflecting the complexity of patients GPs see
in their daily practice.
This is the only study we can identify that uses a con-
sultant physician to detail general practitioners. A recent
study adopted AD to improve end-of-life care in the ICU
setting [26]. However, AD was only one of five compo-
nents of the interventions that included: education of cli-
nicians about palliative care using a variety of approaches
and training of champions. In the ICU study, the interven-
tion had no measurable effect on ratings of the quality of
dying or family satisfaction. However, it is not clear how
the academic detailing was conducted [26].
This pilot study, by contrast, utilised well-established AD
principles. Results illustrate the potential of targeted AD
by a specialist consultant to GPs, enhancing their know-
ledge of diagnosis of reversible causes and management
and confidence in dealing with symptomatic breathlessness
for specific patients. Establishing the feasibility and accept-
ability of AD by a local specialist to GPs in the care of
people with breathlessness represents an important step in
advancing AD as a strategy for improving the safety and
quality of clinical management for this population.
The value GPs placed on AD in this study may be as-
sociated with having a detailer with extensive credible
clinical experience and expertise as both a palliative and
respiratory physician who was able to integrate the spe-
cific key messages with a patient specific discussion, and
who was known and trusted by the local GP community.
As health care systems in resource rich countries face
the prospect of the ageing population and caring for
people with multiple morbidities and their associated
symptoms, the resources of specialist services will come
under increasing resource pressure. Building the capacity
of the existing workforce to adopt new evidence as it
emerges using innovative and cost effective strategies
will be critical. Palliative care skills are often best ac-
quired when facilitated in an experiential format [27].
Academic detailing by a local specialist may provide one
strategy to facilitate practice change where the behav-
ioural goal relates to increasing diagnostic skills and
confidence to support best practice palliative clinical
management.
Limitations
The main limitation of the study was the ultimate
change for patients was not measured, but this will be a
specific outcome measure in the fully powered study.
While GPs rated the visits from the specialist positively,
it is unknown if these visits translated into behaviour
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crucial outcome in a subsequent adequately powered
study. AD is associated with significant upfront costs but
is a very effective intervention, limited most frequently
by the ability to timetable visits.
Conclusions
Overall the delivery of academic detailing by a specialist
was valued by GPs in terms of acceptability and feasibility.
AD may have an important role in the translation of
evidence-to-practice in the diagnosis and clinical manage-
ment of refractory breathlessness and other symptoms at
the end of life. Further research is required to determine if
academic detailing translates into improved patient out-
comes in the palliative care setting in managing refractory
breathlessness. This pilot supports a fully powered study.
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